Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.35 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10048538 | 0.90 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL12973185 | 0.87 | ALDH1A1 (0.48) | GAALMNAALDH1A1TSHRKMT2A | |
| SCHEMBL18521255 | 0.87 | ALDH1A1 (0.48) | GAALMNAALDH1A1TSHRKMT2A | |
| SCHEMBL13607677 | 0.87 | ALDH1A1 (0.48) | GAALMNAALDH1A1TSHRKMT2A | |
| SCHEMBL18510837 | 0.87 | LMNA (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL10017435 | 0.87 | LMNA (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL13170885 | 0.86 | LGALS9 (0.38) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL18510829 | 0.86 | LGALS9 (0.38) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL15849800 | 0.82 | ALDH1A1 (0.35) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA | |
| SCHEMBL13848178 | 0.82 | ALDH1A1 (0.35) | LGALS9LGALS1LGALS3LGALS7; LGALS7BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765933-B2 | Asynthesis of β-nucleosides | PHARMAESSENTIA CORP. (TW) | 2014-07-01 | — | — | US | disclosed |
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | PHARMAESSENTIA CORP. (TW) | 2012-10-11 | — | — | US | disclosed |
| US-8193339-B2 | Synthesis of β-nucleosides | PHARMAESSENTIA CORP. (TW) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | ATIC, DPYD, DUT | LGALS9 4392/4885LGALS1 4680/4885LGALS3 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.